Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuromuscular Deficits Clear all
Withdrawn Not applicable Interventional

Effects of Whole Body Vibration in Elderly Patients Requiring Rehabilitation: A Pilot Study

NCT00610298
View directory record Official record
Conditions
Neuromuscular Deficits, Musculoskeletal Deficits
Interventions
whole body vibration using a Galileo vibrating platform
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Oct 21, 2026, 2:56 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)

NCT06792500
View directory record Official record
Conditions
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
Interventions
Glycerol Tributyrate
Drug
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 21, 2026, 2:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Olfactory Deficits in Neurologic Disease

NCT05019014
View directory record Official record
Conditions
Alzheimer Disease, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Lewy Body Disease, Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 21, 2026, 2:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Behavioral Effects of Obstructive Sleep Apnea in Children

NCT00060723
View directory record Official record
Conditions
Sleep-disordered Breathing, Sleep Apnea, Obstructive, ADHD
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
5 Years to 12 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 21, 2026, 2:56 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Implementation Strategies for Caregiver and Teacher Use of Behavioral Interventions: Aim 2

NCT07321327
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder Symptoms
Interventions
Positive Behavior Management Toolkit for Caregivers, Positive Behavioral Management Toolkit for Teachers
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Not applicable Interventional

Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1

NCT05377008
View directory record Official record
Conditions
Neurocognitive Deficit, Mental Health Impairment, Neurofibromatosis 1
Interventions
OPTIMAL-SSI
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
6 Years to 16 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Not applicable Interventional Results available

The KNEEhabilitation Study: Improving Disability in Individuals With Knee Osteoarthritis

NCT02634814
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Transcutaneous Electrical Nerve Stimulation, Therapeutic Exercise, Sham Transcutaneous Electrical Nerve Stimulation
Device · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

NCT01338818
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
Ritalin LA (methylphenidate hydrochloride extended release)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
16
States / cities
Little Rock, Arkansas • Beverly Hills, California • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Not applicable Interventional Results available

Spinal Cord Stimulation in Spinal Muscular Atrophy

NCT05430113
View directory record Official record
Conditions
Spinal Muscular Atrophy Type 3, Spinal Muscular Atrophy Type 4
Interventions
Spinal Cord Stimulator (octopolar Medtronic Vectris Leads)
Device
Lead sponsor
Marco Capogrosso
Other
Eligibility
16 Years to 64 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach

NCT01678209
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, ADHD
Interventions
fMRI scans, Atomoxetine arm, Methylphenidate arm
Other · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
7 Years to 17 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Dietary Protein on Musculoskeletal Health During Calorie Deficiency

NCT01292395
View directory record Official record
Conditions
Weight Loss, Muscle Loss, Bone Loss
Interventions
Dietary Protein Intake
Other
Lead sponsor
United States Army Research Institute of Environmental Medicine
Federal
Eligibility
18 Years to 42 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2017 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT03327402
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465
Drug
Lead sponsor
Shire
Industry
Eligibility
4 Years to 5 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
8
States / cities
Little Rock, Arkansas • Orlando, Florida • Evansville, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 21, 2026, 2:56 PM EDT
Recruiting No phase listed Observational

The Myelin Disorders Biorepository Project

NCT03047369
View directory record Official record
Conditions
Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication | Blood or Tissue | Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2030
U.S. locations
23
States / cities
Los Angeles, California • Orange, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

Early Neuromuscular Electrical Stimulation For Quadriceps Muscle Activation Deficits Following Total Knee Replacement

NCT00800254
View directory record Official record
Conditions
Osteoarthritis
Interventions
Neuromuscular Electrical Stimulation (NMES), Standard Rehabilitation Protocol
Device · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years to 85 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 11, 2015 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-9855 Mass Balance Study

NCT01924143
View directory record Official record
Conditions
ADHD, Fibromyalgia
Interventions
TD-9855
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 50 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1

NCT04481048
View directory record Official record
Conditions
Neurofibromatosis 1
Interventions
N-Acetyl cysteine, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 16 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Results available

Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder

NCT01238575
View directory record Official record
Conditions
Pervasive Development Disorders
Interventions
placebo, extended-release guanfacine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
5 Years to 14 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
5
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

NCT01074294
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
OPDC-34712, Placebo, Stimulant Therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2023 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 3 Interventional

Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00556959
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
high dose clonidine HCl sustained release, low dose clonidine HCl sustained release, placebo
Drug
Lead sponsor
Addrenex Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Gainesville, Florida • Jacksonville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 21, 2026, 2:56 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Influence of Directional Preference on Movement Coordination Deficits in Individuals With Whiplash Associated Disorders

NCT06143228
View directory record Official record
Conditions
Whiplash Injury of Cervical Spine, Muscle Weakness
Interventions
Not listed
Lead sponsor
D'Youville College
Other
Eligibility
19 Years to 70 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Tallahassee, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Phase 3 Interventional

Effect of Working Memory Training on ADHD Brain Function

NCT02151396
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder (Combined-subtype)
Interventions
Working memory training, Functional magnetic resonance imaging (fMRI)
Behavioral · Device
Lead sponsor
Hartford Hospital
Other
Eligibility
13 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 21, 2026, 2:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

NCT05945784
View directory record Official record
Conditions
Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute, Traumatic Brain Injury, SCI - Spinal Cord Injury, Ehlers-Danlos Syndromes (EDS), Lupus Erythematosus, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Graves Disease, Muscular Dystrophies
Interventions
Use of Rare Beauty makeup products
Other
Lead sponsor
Casa Colina Hospital and Centers for Healthcare
Other
Eligibility
18 Years to 55 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Pomona, California
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Oct 21, 2026, 2:56 PM EDT
Completed Not applicable Interventional

Addressing Neuromuscular Deficits for Improved Outcomes in Ankle Rehabilitation

NCT03663361
View directory record Official record
Conditions
Ankle Sprains
Interventions
SMART Intervention, Standard of Care Intervention
Other
Lead sponsor
Phillip Gribble
Other
Eligibility
18 Years to 44 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Lexington, Kentucky • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 21, 2026, 2:56 PM EDT
Not listed Not applicable Interventional

Enhancing ADHD Driving Performance With Stimulant Medication

NCT00572026
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 25 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Oct 21, 2026, 2:56 PM EDT